13 June 1997
Non-immunefactors in chronic rejection. Is there a role for hypolipemic drugs?
Leszek Paczek, Marta BiIl, Janusz Wyzgal, Liliana Gradowska, Zbigniew Galazka, Zbigniew GaciongAnn Transplant 1997; 2(2): 65-69 :: ID: 497163
Abstract
The high prevalence of hypercholesterolemia in kidney transplant recipients probably contributes to the high cardiovascular mortality in these patients and may be a factor contributing to the progression of renal failure. We randomized 42 renal allograft recipients to receive low dose (20 mg) lovastatin or placebo for 32 weeks. All patients had stable graft function (serum creatinine level
Keywords: Kidney Transplantation, lovastatin, lovastatin
In Press
Original article
Learning Curve and Outcomes of Pure Laparoscopic Donor Major Hepatectomy Performed by Fellowship-Trained Su...Ann Transplant In Press; DOI: 10.12659/AOT.953061
Original article
Role of Psychological Resilience on Emotional Health in Kidney and Liver Transplant RecipientsAnn Transplant In Press; DOI: 10.12659/AOT.952824
Original article
Analysis of Factors Influencing the Psychological State of Patients After Autologous Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.953645
Original article
Fundamental Strategies and Technical Perspectives in Bile Duct Anastomosis for Living Donor Liver Transplan...Ann Transplant In Press; DOI: 10.12659/AOT.953761
Most Viewed Current Articles
24 Aug 2021 : Review article 21,725
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article 17,946
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
22 Nov 2022 : Original article 16,696
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
05 Apr 2022 : Original article 16,590
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604